Literature DB >> 8931942

Investigation on QSAR and binding mode of a new class of human rhinovirus-14 inhibitors by CoMFA and docking experiments.

M Artico1, M Botta, F Corelli, A Mai, S Massa, R Ragno.   

Abstract

A 3-D QSAR study has been carried out on a new class of potent and selective human rhinovirus-14 (HRV-14) inhibitors. In particular, the CoMFA (comparative molecular field analysis) technique has been applied to develop a model able to explain and predict the anti-HRV-14 activity of a class of compounds 4 and potentially helpful to design new and more potent antirhinovirus agents. Docking experiments have also been performed with the aim of elucidating the possible binding mode of these inhibitors. These two approaches are combined to highlight a single, highly favoured mode of interaction of the compounds with the viral capsid proteins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8931942     DOI: 10.1016/0968-0896(96)00184-8

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

1.  Studies of H4R antagonists using 3D-QSAR, molecular docking and molecular dynamics.

Authors:  Jing Liu; Yan Li; Hui-Xiao Zhang; Shu-Wei Zhang; Ling Yang
Journal:  J Mol Model       Date:  2011-06-07       Impact factor: 1.810

2.  Homology model directed alignment selection for comparative molecular field analysis: application to photosystem II inhibitors.

Authors:  M Jalaie; J A Erickson
Journal:  J Comput Aided Mol Des       Date:  2000-02       Impact factor: 3.686

3.  Studies of new fused benzazepine as selective dopamine D3 receptor antagonists using 3D-QSAR, molecular docking and molecular dynamics.

Authors:  Jing Liu; Yan Li; Shuwei Zhang; Zhengtao Xiao; Chunzhi Ai
Journal:  Int J Mol Sci       Date:  2011-02-18       Impact factor: 5.923

Review 4.  The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery.

Authors:  Judith M Rollinger; Michaela Schmidtke
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.